AI Article Synopsis
- The text discusses the creation and biological testing of new generation 5 PAMAM dendrimers linked with riboflavin for targeted therapy.
- Lab tests showed that riboflavin-conjugated dendrimers can attach to and enter KB cells effectively.
- Additionally, when these dendrimers are combined with methotrexate, they significantly inhibit the growth of these cancer cells.
Article Abstract
This communication describes the synthesis and in vitro biological evaluation of novel generation 5 PAMAM dendrimers conjugated with riboflavin as a targeting ligand. Cell-based experiments demonstrated that a dendrimer conjugated with riboflavin is able to undergo cellular binding and uptake in KB cells, and when the dendrimer is also conjugated with methotrexate, the riboflavin dendrimer conjugate can potently inhibit cell growth.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922453 | PMC |
| http://dx.doi.org/10.1016/j.bmcl.2010.07.005 | DOI Listing |
Publication Analysis
Top Keywords
pamam dendrimers
8
conjugated riboflavin
8
dendrimer conjugated
8
design riboflavin-presenting
4
riboflavin-presenting pamam
4
dendrimers nanoplatform
4
nanoplatform cancer-targeted
4
cancer-targeted delivery
4
delivery communication
4
communication describes
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!